首页 理论教育 联合降压治疗原则

联合降压治疗原则

时间:2022-03-13 理论教育 版权反馈
【摘要】:1.药物搭配应具有协同性。尽量联用两种不同降压机制的药物,常为小剂量联合,以降低单药高剂量所致的剂量相关性不良反应。4.选择药物时还应注意是否有利于改善靶器官损害,减少心脑血管事件、肾病或糖尿病,以及有无对某种疾病的禁忌。

联合用药时应注意遵循以下原则。

1.药物搭配应具有协同性。尽量联用两种不同降压机制的药物,常为小剂量联合,以降低单药高剂量所致的剂量相关性不良反应

2.联合用药时各种药物的不良反应最好相互抵消或少于两药单用。

3.为简化治疗,提高患者依从性,联用药物需服用方便,每日1次,疗效持续24h以上。

4.选择药物时还应注意是否有利于改善靶器官损害,减少心脑血管事件、肾病或糖尿病,以及有无对某种疾病的禁忌。

(张 敏)

参考文献

[1] 中国高血压防治指南修订委员会.中国高血压防治指南(2005年修订版),北京:人民卫生出版社,2006.

[2]Mancia G,Backe GD,Dominiczakc A,Cifkova R,Fagarde R,Germanof G,Grassi G,Heagertyh AM,Kjeldseni SE,Laurent S,Narkiewiczk K,Ruilopel L,Rynkiewicz A,Schmieder RE,Struijker Boudier HAJ,Zanchetti A.2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension.ESH-ESC Task Force on the Management of Arterial Hypertension.J Hypertens,2007,25:1751-1762.

[3]Chobanian AV,Bakris GL,Black HR,Cushman WC,Green LA,Izzo JLJ,et al.The Seventh Report of the Joint National Committee on prevention,Detection,Evaluation,and Treatment of High Blood Pressure:the JNC 7report.JAMA,2003,289:2560-2572.

[4]Joint National Committee on Prevention,Detection,Evaluation and Treatment of High Blood Pressure(JNC VI).Arch Intern Med,1997,157:2413-2446.

[5] 刘力生,王文,姚崇华.中国高血压防治指南(2009年基层版).中华高血压杂志,2010,1:18-37.

[6]Dahlf B,Sever PS,Poulter NR,Wedel H,Beevers DG,Caulfield M,Collins R,Kjeldsen SE,Kristinsson A,McInnes GT,Mehlsen J,Nieminen M,O'Brien E,stergren J,the ASCOT investigators.Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required,in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA):a multicentre randomised controlled trial.Lancet,2005,366:895-906.

[7]Gradman AH,Acevedo C.Evolving strategies for the use of combination therapy in hypertension.Current Hypertension Reports,2002,4:343-349.

[8]Gradman AH,Cutler NR,Davis PJ,Robbins JA,Weiss RJ,Wood BC.Combined enalapril and felodipine extended release(ER)for systemic hypertension.Enalapril-Felodipine ER Factorial Study Group.Am J Cardiol,1997,79:431-435.

[9]Elliott WJ.Isxed combination therapy appropriate for initial hypertension treatment?Current Hypertension Reports,2002,4:278-285.

[10]Messerli FH,Oparil S,Feng Z.Comparison of efcacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril)with calcium antagonist(either nifedipine or amlodipine)versus high-dose calcium antagonist monotherapy for systemic hypertension.Am J Cardiol,2000,86:1182-1187.

[11]Destro M,Luckow A,Samson M,Kandra A,Brunel P.Efficacy and safety of amlodipine/valsartan compared with amlodipine monotherapy in patients with stage 2hypertension:a randomized,double-blind,multicenter study:the EX-EFFeCTS Study.J Am Soc Hypertens,2008,2:294-302.

[12]Kostis JB.Antihypertensive Therapy With CCB/ARB Combination in Older Individuals:Focus on Amlodipine/Valsartan Combination.Am J Therapeut,2010,17:188-196.

[13]The ONTARGET Investigators.Telmisartan,Ramipril,or Both in Patients at High Risk for Vascular Events.New Engl J Med,2008,358: 1547-1559.

[14]Kunz R,Friedrich C,Wolbers M,Mann J.F.E.Meta-analysis:Effect of Monotherapy and Combination Therapy with Inhibitors of the Renin-Angiotensin System on Proteinuria in Renal Disease.Ann Intern Med,2008,148:30-48.

[15]The SOLVD Investigators.Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.N Engl J Med,1991,325:293-302.

[16]Kleber FX,Niemller L,Doering W.Impact of converting enzyme inhibition on progression of chronic heart failure:results of the Munich Mild Heart Failure Trial.Br Heart J,1992,67:289-296.

[17]Swedberg K,Held P,Kjekshun J,Rasmussen K,Ryden L,Wedel H.Effect of the early administration of enalapril on mortality in the patients with acute myocardial infarction.Results of the Cooperative New Scandinavian Enalapril Survival Study II(CONSENSUS II).N Engl J Med,1992,327:678-684.

[18]Pitt B.Evaluation of Losartan in the Elderly (ELITE)Trial:clinical implications.Eur Heart J,1997,18:1197-1199.

[19]Di L,Maria R De,Gavazzi A,Gregori D,Parolini M,Sinagra G,Salvatore L,Longaro F,Bernobich E,Camerini F.Long term survival effect of metoprolol in dilated cardiomyopathy.Heart,1998,79:337-344.

[20]CIBIS Investigators and Committees.A randomized trial of beta-blockade in heart failure.The Cardiac Insufficiency Bisoprolol Study (CIBIS).Circulation,1994,90:1765-1773.

[21]The HOPE Study Investigators.Vitamin E supplementation and cardiovascular events in high-risk patients.N Engl J Med,2000,342: 154-160.

[22]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.β肾上腺素能受体阻滞剂在心血管疾病应用专家共识.中华心血管病杂志,2009,37:195-209.

[23]Waeber B.Fixed low-dose combinations for hypertension.Current hypertension Reports,2002,4:298-306.

[24]Waeber B,Brunner HR.Low-dose combinations versus monotherapies in the treatment of hypertension.J Hypertens,1997,5(suppl 2):17-20.

[25]Neutel JM,Smith DH,Weber MA.Low-dose combination therapy:an importantrst-line treatment in the management of hypertension.Am J Hypertens,2001,14:286-292.

[26]MacKay JH,Arcuri KE,Goldberg AI,Snapinn SM,Sweet CS.Losartan and low-dose hydrochlorothiazide in patients with essential hypertension.A double-blind,placebo-controlled trial of concomitant administration compared with individual components.Arch Intern Med,1996,156:278-285.

[27]Neutel JM,Saunders E,Bakris GL,Cushman WC,Ferdinand KC,Ofili EO,Sowers JR,Weber MA.The efficacy and safety of low-and high-dose fixed combinations of Irbesartan/Hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy:The INCLUSIVE Trial.J Clin Hypertens,2005,7:578-586.

[28]Allemann Y,Fraile B,Lambert M,Barbier M,Ferber P,Izzo JL.Efficacy of the Combination of Amlodipine and Valsartan in Patients With Hypertension Uncontrolled With Previous Monotherapy:The Exforge in Failure After Single Therapy(EX-FAST)Study.J Clin Hypertens,2008,10:185-194.

免责声明:以上内容源自网络,版权归原作者所有,如有侵犯您的原创版权请告知,我们将尽快删除相关内容。

我要反馈